OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc (AQSE: PBX) (“ProBiotix Health”), that Steen Andersen (“Steen”) has been appointed as Chief Executive Officer (“CEO”), and that Steen will join the company after completing his notice period with his current employer.
The Company has a 44 per cent. shareholding in ProBiotix Health.
This is part of a long-planned strategy by OptiBiotix and its portfolio companies (the “Group”) to appoint experienced industry commercial leaders to each part of the business allowing the Group CEO to focus on identifying, developing and acquiring the new technologies or companies that will provide the Group with a pipeline of products and applications to deliver future growth and market value. This structure gives shareholders exposure to multiple opportunities within the emerging microbiome space and affords the potential to deliver additional value through separate public listing of the businesses and dividend return as achieved with the listing of ProBiotix Health earlier in the year.
Stephen O’Hara, CEO of OptiBiotix, commented: “The appointment of Steen as CEO of ProBiotix Health will help accelerate the growth and recognition of the business into its next phase of evolution. Having established international sales and brand awareness of its award winning LPLDL® probiotic as an ingredient, ProBiotix Health is now investing in building a presence in the dairy industry, extending the range of applications for LPLDL® into other areas of health, and increasing access to the USA and Asian markets.”
For further information, please contact:
OptiBiotix Health plc
Stephen O’Hara, Chief Executive
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned